Amphastar Pharmaceuticals已同南京汉欣医药科技有限公司签署一项授权协议,涉及一款全合成促肾上腺皮质激素化合物的开发与商业化。该合作旨在拓展双方在激素类药物领域的产品管线,为特定内分泌疾病患者提供新的治疗选择。
Amphastar Pharmaceuticals已同南京汉欣医药科技有限公司签署一项授权协议,涉及一款全合成促肾上腺皮质激素化合物的开发与商业化。该合作旨在拓展双方在激素类药物领域的产品管线,为特定内分泌疾病患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.